Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.47 |
| ▸ | RORB | Q92753 | 2/20 | 0.42 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | PTPRF | P10586 | 1/20 | 0.39 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | PTPRA | P18433 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30173780 | 1.00 | DHODH (0.47) | DHODHRORBIGF2BP2PTPN1PTPRF | |
| SCHEMBL30173735 | 0.93 | DHODH (0.49) | DHODHRORBPOLBMAPTKMT2A | |
| SCHEMBL23782583 | 0.93 | DHODH (0.49) | DHODHRORBPOLBMAPTKMT2A | |
| SCHEMBL26242452 | 0.90 | PTPN1 (0.39) | DHODHPTPN1PTPRFRORCMEN1 | |
| SCHEMBL23791737 | 0.89 | IGF2BP2 (0.46) | DHODHIGF2BP2PTPN1PTPRFRORC | |
| SCHEMBL26241850 | 0.88 | PTPN1 (0.41) | DHODHIGF2BP2PTPN1PTPRFRORC | |
| SCHEMBL26242454 | 0.86 | DHODH (0.45) | DHODHIGF2BP2PTPN1PTPRFRORC | |
| SCHEMBL23782401 | 0.82 | DHODH (0.45) | DHODHRORBRAPGEF3RAPGEF4RORC | |
| SCHEMBL30173772 | 0.82 | DHODH (0.45) | DHODHRORBRAPGEF3RAPGEF4RORC | |
| SCHEMBL23791736 | 0.82 | DHODH (0.47) | DHODHRORBRORCMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4114529-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2022-11-10 | — | — | US | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | DHODH 3236/4885RORB 2834/4885IGF2BP2 255/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | DHODH 3236/4885RORB 2834/4885IGF2BP2 255/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | DHODH 3236/4885RORB 2834/4885IGF2BP2 255/4885 |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | DHODH 3236/4885RORB 2834/4885IGF2BP2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.